Hepatic Unsaturated Fatty Acids Are Linked to Lower Degree of Fibrosis in Non-alcoholic Fatty Liver Disease
Background: The hepatic lipidome of patients with early stages of non-alcoholic fatty liver disease (NAFLD) has been fairly well-explored. However, studies on more progressive forms of NAFLD, i.e., liver fibrosis, are limited. Materials and methods: Liver fatty acids were determined in cholesteryl e...
Saved in:
| Published in | Frontiers in medicine Vol. 8; p. 814951 |
|---|---|
| Main Authors | , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Switzerland
Frontiers Media S.A
10.01.2022
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 2296-858X 2296-858X |
| DOI | 10.3389/fmed.2021.814951 |
Cover
| Abstract | Background:
The hepatic lipidome of patients with early stages of non-alcoholic fatty liver disease (NAFLD) has been fairly well-explored. However, studies on more progressive forms of NAFLD, i.e., liver fibrosis, are limited.
Materials and methods:
Liver fatty acids were determined in cholesteryl esters (CE), phospholipids (PL), and triacylglycerols (TAG) by gas chromatography. Cross-sectional associations between fatty acids and biopsy-proven NAFLD fibrosis (
n
= 60) were assessed using multivariable logistic regression models. Stages of fibrosis were dichotomized into none-mild (F0–1) or significant fibrosis (F2–4). Models were adjusted for body-mass index (BMI), age and patatin-like phospholipase domain-containing protein 3 (PNPLA3 rs738409) (I148M) genotype. A secondary analysis examined whether associations from the primary analysis could be confirmed in the corresponding plasma lipid fractions.
Results:
PL behenic acid (22:0) was directly associated [OR (95% CI): 1.86 (1.00, 3.45)] whereas PL docosahexaenoic acid (22:6n-3) [OR (95% CI): 0.45 (0.23, 0.89)], TAG oleic acid (18:1n-9) [OR (95% CI): 0.52 (0.28, 0.95)] and 18:1n-9 and vaccenic acid (18:1n-7) (18:1) [OR (95% CI): 0.52 (0.28, 0.96)] were inversely associated with liver fibrosis. In plasma, TAG 18:1n-9 [OR (95% CI): 0.55 (0.31, 0.99)], TAG 18:1 [OR (95% CI): 0.54 (0.30, 0.97)] and PL 22:0 [OR (95% CI): 0.46 (0.25, 0.86)] were inversely associated with liver fibrosis.
Conclusion:
Higher TAG 18:1n-9 levels were linked to lower fibrosis in both liver and plasma, possibly reflecting an altered fatty acid metabolism. Whether PL 22:6n-3 has a protective role, together with a potentially adverse effect of hepatic 22:0, on liver fibrosis warrants large-scale studies. |
|---|---|
| AbstractList | Background: The hepatic lipidome of patients with early stages of non-alcoholic fatty liver disease (NAFLD) has been fairly well-explored. However, studies on more progressive forms of NAFLD, i.e., liver fibrosis, are limited.
Materials and methods: Liver fatty acids were determined in cholesteryl esters (CE), phospholipids (PL), and triacylglycerols (TAG) by gas chromatography. Cross-sectional associations between fatty acids and biopsy-proven NAFLD fibrosis (n = 60) were assessed using multivariable logistic regression models. Stages of fibrosis were dichotomized into none-mild (F0–1) or significant fibrosis (F2–4). Models were adjusted for body-mass index (BMI), age and patatin-like phospholipase domain-containing protein 3 (PNPLA3 rs738409) (I148M) genotype. A secondary analysis examined whether associations from the primary analysis could be confirmed in the corresponding plasma lipid fractions.
Results: PL behenic acid (22:0) was directly associated [OR (95% CI): 1.86 (1.00, 3.45)] whereas PL docosahexaenoic acid (22:6n-3) [OR (95% CI): 0.45 (0.23, 0.89)], TAG oleic acid (18:1n-9) [OR (95% CI): 0.52 (0.28, 0.95)] and 18:1n-9 and vaccenic acid (18:1n-7) (18:1) [OR (95% CI): 0.52 (0.28, 0.96)] were inversely associated with liver fibrosis. In plasma, TAG 18:1n-9 [OR (95% CI): 0.55 (0.31, 0.99)], TAG 18:1 [OR (95% CI): 0.54 (0.30, 0.97)] and PL 22:0 [OR (95% CI): 0.46 (0.25, 0.86)] were inversely associated with liver fibrosis.
Conclusion: Higher TAG 18:1n-9 levels were linked to lower fibrosis in both liver and plasma, possibly reflecting an altered fatty acid metabolism. Whether PL 22:6n-3 has a protective role, together with a potentially adverse effect of hepatic 22:0, on liver fibrosis warrants large-scale studies. Background: The hepatic lipidome of patients with early stages of non-alcoholic fatty liver disease (NAFLD) has been fairly well-explored. However, studies on more progressive forms of NAFLD, i.e., liver fibrosis, are limited. Materials and methods: Liver fatty acids were determined in cholesteryl esters (CE), phospholipids (PL), and triacylglycerols (TAG) by gas chromatography. Cross-sectional associations between fatty acids and biopsy-proven NAFLD fibrosis ( n = 60) were assessed using multivariable logistic regression models. Stages of fibrosis were dichotomized into none-mild (F0–1) or significant fibrosis (F2–4). Models were adjusted for body-mass index (BMI), age and patatin-like phospholipase domain-containing protein 3 (PNPLA3 rs738409) (I148M) genotype. A secondary analysis examined whether associations from the primary analysis could be confirmed in the corresponding plasma lipid fractions. Results: PL behenic acid (22:0) was directly associated [OR (95% CI): 1.86 (1.00, 3.45)] whereas PL docosahexaenoic acid (22:6n-3) [OR (95% CI): 0.45 (0.23, 0.89)], TAG oleic acid (18:1n-9) [OR (95% CI): 0.52 (0.28, 0.95)] and 18:1n-9 and vaccenic acid (18:1n-7) (18:1) [OR (95% CI): 0.52 (0.28, 0.96)] were inversely associated with liver fibrosis. In plasma, TAG 18:1n-9 [OR (95% CI): 0.55 (0.31, 0.99)], TAG 18:1 [OR (95% CI): 0.54 (0.30, 0.97)] and PL 22:0 [OR (95% CI): 0.46 (0.25, 0.86)] were inversely associated with liver fibrosis. Conclusion: Higher TAG 18:1n-9 levels were linked to lower fibrosis in both liver and plasma, possibly reflecting an altered fatty acid metabolism. Whether PL 22:6n-3 has a protective role, together with a potentially adverse effect of hepatic 22:0, on liver fibrosis warrants large-scale studies. Background: The hepatic lipidome of patients with early stages of non-alcoholic fatty liver disease (NAFLD) has been fairly well-explored. However, studies on more progressive forms of NAFLD, i.e., liver fibrosis, are limited.Materials and methods: Liver fatty acids were determined in cholesteryl esters (CE), phospholipids (PL), and triacylglycerols (TAG) by gas chromatography. Cross-sectional associations between fatty acids and biopsy-proven NAFLD fibrosis (n = 60) were assessed using multivariable logistic regression models. Stages of fibrosis were dichotomized into none-mild (F0–1) or significant fibrosis (F2–4). Models were adjusted for body-mass index (BMI), age and patatin-like phospholipase domain-containing protein 3 (PNPLA3 rs738409) (I148M) genotype. A secondary analysis examined whether associations from the primary analysis could be confirmed in the corresponding plasma lipid fractions.Results: PL behenic acid (22:0) was directly associated [OR (95% CI): 1.86 (1.00, 3.45)] whereas PL docosahexaenoic acid (22:6n-3) [OR (95% CI): 0.45 (0.23, 0.89)], TAG oleic acid (18:1n-9) [OR (95% CI): 0.52 (0.28, 0.95)] and 18:1n-9 and vaccenic acid (18:1n-7) (18:1) [OR (95% CI): 0.52 (0.28, 0.96)] were inversely associated with liver fibrosis. In plasma, TAG 18:1n-9 [OR (95% CI): 0.55 (0.31, 0.99)], TAG 18:1 [OR (95% CI): 0.54 (0.30, 0.97)] and PL 22:0 [OR (95% CI): 0.46 (0.25, 0.86)] were inversely associated with liver fibrosis.Conclusion: Higher TAG 18:1n-9 levels were linked to lower fibrosis in both liver and plasma, possibly reflecting an altered fatty acid metabolism. Whether PL 22:6n-3 has a protective role, together with a potentially adverse effect of hepatic 22:0, on liver fibrosis warrants large-scale studies. Background: The hepatic lipidome of patients with early stages of non-alcoholic fatty liver disease (NAFLD) has been fairly well-explored. However, studies on more progressive forms of NAFLD, i.e., liver fibrosis, are limited. Materials and methods: Liver fatty acids were determined in cholesteryl esters (CE), phospholipids (PL), and triacylglycerols (TAG) by gas chromatography. Cross-sectional associations between fatty acids and biopsy-proven NAFLD fibrosis (n = 60) were assessed using multivariable logistic regression models. Stages of fibrosis were dichotomized into none-mild (F0-1) or significant fibrosis (F2-4). Models were adjusted for body-mass index (BMI), age and patatin-like phospholipase domain-containing protein 3 (PNPLA3 rs738409) (I148M) genotype. A secondary analysis examined whether associations from the primary analysis could be confirmed in the corresponding plasma lipid fractions. Results: PL behenic acid (22:0) was directly associated [OR (95% CI): 1.86 (1.00, 3.45)] whereas PL docosahexaenoic acid (22:6n-3) [OR (95% CI): 0.45 (0.23, 0.89)], TAG oleic acid (18:1n-9) [OR (95% CI): 0.52 (0.28, 0.95)] and 18:1n-9 and vaccenic acid (18:1n-7) (18:1) [OR (95% CI): 0.52 (0.28, 0.96)] were inversely associated with liver fibrosis. In plasma, TAG 18:1n-9 [OR (95% CI): 0.55 (0.31, 0.99)], TAG 18:1 [OR (95% CI): 0.54 (0.30, 0.97)] and PL 22:0 [OR (95% CI): 0.46 (0.25, 0.86)] were inversely associated with liver fibrosis. Conclusion: Higher TAG 18:1n-9 levels were linked to lower fibrosis in both liver and plasma, possibly reflecting an altered fatty acid metabolism. Whether PL 22:6n-3 has a protective role, together with a potentially adverse effect of hepatic 22:0, on liver fibrosis warrants large-scale studies.Background: The hepatic lipidome of patients with early stages of non-alcoholic fatty liver disease (NAFLD) has been fairly well-explored. However, studies on more progressive forms of NAFLD, i.e., liver fibrosis, are limited. Materials and methods: Liver fatty acids were determined in cholesteryl esters (CE), phospholipids (PL), and triacylglycerols (TAG) by gas chromatography. Cross-sectional associations between fatty acids and biopsy-proven NAFLD fibrosis (n = 60) were assessed using multivariable logistic regression models. Stages of fibrosis were dichotomized into none-mild (F0-1) or significant fibrosis (F2-4). Models were adjusted for body-mass index (BMI), age and patatin-like phospholipase domain-containing protein 3 (PNPLA3 rs738409) (I148M) genotype. A secondary analysis examined whether associations from the primary analysis could be confirmed in the corresponding plasma lipid fractions. Results: PL behenic acid (22:0) was directly associated [OR (95% CI): 1.86 (1.00, 3.45)] whereas PL docosahexaenoic acid (22:6n-3) [OR (95% CI): 0.45 (0.23, 0.89)], TAG oleic acid (18:1n-9) [OR (95% CI): 0.52 (0.28, 0.95)] and 18:1n-9 and vaccenic acid (18:1n-7) (18:1) [OR (95% CI): 0.52 (0.28, 0.96)] were inversely associated with liver fibrosis. In plasma, TAG 18:1n-9 [OR (95% CI): 0.55 (0.31, 0.99)], TAG 18:1 [OR (95% CI): 0.54 (0.30, 0.97)] and PL 22:0 [OR (95% CI): 0.46 (0.25, 0.86)] were inversely associated with liver fibrosis. Conclusion: Higher TAG 18:1n-9 levels were linked to lower fibrosis in both liver and plasma, possibly reflecting an altered fatty acid metabolism. Whether PL 22:6n-3 has a protective role, together with a potentially adverse effect of hepatic 22:0, on liver fibrosis warrants large-scale studies. The hepatic lipidome of patients with early stages of non-alcoholic fatty liver disease (NAFLD) has been fairly well-explored. However, studies on more progressive forms of NAFLD, i.e., liver fibrosis, are limited. Liver fatty acids were determined in cholesteryl esters (CE), phospholipids (PL), and triacylglycerols (TAG) by gas chromatography. Cross-sectional associations between fatty acids and biopsy-proven NAFLD fibrosis ( = 60) were assessed using multivariable logistic regression models. Stages of fibrosis were dichotomized into none-mild (F0-1) or significant fibrosis (F2-4). Models were adjusted for body-mass index (BMI), age and patatin-like phospholipase domain-containing protein 3 (PNPLA3 rs738409) (I148M) genotype. A secondary analysis examined whether associations from the primary analysis could be confirmed in the corresponding plasma lipid fractions. PL behenic acid (22:0) was directly associated [OR (95% CI): 1.86 (1.00, 3.45)] whereas PL docosahexaenoic acid (22:6n-3) [OR (95% CI): 0.45 (0.23, 0.89)], TAG oleic acid (18:1n-9) [OR (95% CI): 0.52 (0.28, 0.95)] and 18:1n-9 and vaccenic acid (18:1n-7) (18:1) [OR (95% CI): 0.52 (0.28, 0.96)] were inversely associated with liver fibrosis. In plasma, TAG 18:1n-9 [OR (95% CI): 0.55 (0.31, 0.99)], TAG 18:1 [OR (95% CI): 0.54 (0.30, 0.97)] and PL 22:0 [OR (95% CI): 0.46 (0.25, 0.86)] were inversely associated with liver fibrosis. Higher TAG 18:1n-9 levels were linked to lower fibrosis in both liver and plasma, possibly reflecting an altered fatty acid metabolism. Whether PL 22:6n-3 has a protective role, together with a potentially adverse effect of hepatic 22:0, on liver fibrosis warrants large-scale studies. |
| Author | Rorsman, Fredrik Fridén, Michael Niessen, Heiko G. Wanders, Alkwin Hockings, Paul Schultheis, Christian Gummesson, Anders Risérus, Ulf Hulthe, Johannes Ahlström, Håkan Rosqvist, Fredrik Vessby, Johan |
| AuthorAffiliation | 1 Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University , Uppsala , Sweden 4 Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach , Germany 3 Antaros Medical AB, BioVenture Hub , Mölndal , Sweden 7 Department of Pathology, Aalborg University Hospital , Aalborg , Denmark 2 Department of Surgical Sciences, Radiology, Uppsala University , Uppsala , Sweden 8 Department of Medical Sciences, Gastroenterology and Hepatology, Uppsala University , Uppsala , Sweden 6 Department of Clinical Genetics and Genomics, Region Västra Götaland, Sahlgrenska University Hospital , Gothenburg , Sweden 5 MedTech West, Chalmers University of Technology , Gothenburg , Sweden |
| AuthorAffiliation_xml | – name: 1 Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University , Uppsala , Sweden – name: 8 Department of Medical Sciences, Gastroenterology and Hepatology, Uppsala University , Uppsala , Sweden – name: 6 Department of Clinical Genetics and Genomics, Region Västra Götaland, Sahlgrenska University Hospital , Gothenburg , Sweden – name: 2 Department of Surgical Sciences, Radiology, Uppsala University , Uppsala , Sweden – name: 3 Antaros Medical AB, BioVenture Hub , Mölndal , Sweden – name: 4 Department of Translational Medicine and Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG , Biberach , Germany – name: 7 Department of Pathology, Aalborg University Hospital , Aalborg , Denmark – name: 5 MedTech West, Chalmers University of Technology , Gothenburg , Sweden |
| Author_xml | – sequence: 1 givenname: Michael surname: Fridén fullname: Fridén, Michael – sequence: 2 givenname: Fredrik surname: Rosqvist fullname: Rosqvist, Fredrik – sequence: 3 givenname: Håkan surname: Ahlström fullname: Ahlström, Håkan – sequence: 4 givenname: Heiko G. surname: Niessen fullname: Niessen, Heiko G. – sequence: 5 givenname: Christian surname: Schultheis fullname: Schultheis, Christian – sequence: 6 givenname: Paul surname: Hockings fullname: Hockings, Paul – sequence: 7 givenname: Johannes surname: Hulthe fullname: Hulthe, Johannes – sequence: 8 givenname: Anders surname: Gummesson fullname: Gummesson, Anders – sequence: 9 givenname: Alkwin surname: Wanders fullname: Wanders, Alkwin – sequence: 10 givenname: Fredrik surname: Rorsman fullname: Rorsman, Fredrik – sequence: 11 givenname: Ulf surname: Risérus fullname: Risérus, Ulf – sequence: 12 givenname: Johan surname: Vessby fullname: Vessby, Johan |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35083257$$D View this record in MEDLINE/PubMed https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-468792$$DView record from Swedish Publication Index https://research.chalmers.se/publication/528478$$DView record from Swedish Publication Index |
| BookMark | eNp1kktv1DAUhSNUREvpnhXKkgUz-P3YII1ahlYawQKK2FmOczPjNhNP7aRV_z1OU6oOUld-nfP5Xvu8LQ660EFRvMdoTqnSn5st1HOCCJ4rzDTHr4ojQrSYKa7-HDybHxYnKV0hhDAlnGH6pjikHKm8kEfF9TnsbO9dedkl2w_R9lCXS9v39-XC-TqViwjlynfXebsP5SrcQSzPYB0BytCUS1_FkHwqfVd-D93Mti5sQpt5E2Plb0e9T2ATvCteN7ZNcPI4HheXy6-_Ts9nqx_fLk4Xq5kTDPczx2xNtLS8qhSWghKsmKyVlI0ERbhlutYIE8lAMZZPaG2pc1A71lSCIU6Pi4uJWwd7ZXbRb228N8F687AR4trYmHtuwTBBMa8Zr6ykrFHCAkKNJhJxRhrlILN-Tqx0B7uh2qNFyG1FtzFuY9stxGQSGCy05hZho0VDM5-A0ZQ5g7lAwB2toNaZ-ulF6pn_vXiocRiyXUlNsvzLJM_a_OkOuj7ads-1f9L5jVmHW6OkYlyMgI-PgBhuBki92frkoG1tB2FIhmQNJRqL8fE-PL_r6ZJ_kckCNAlc_vkUoXmSYGTGYJoxmGYMppmCmS3iP4vzfU5dGKv17cvGv99n57Y |
| CitedBy_id | crossref_primary_10_1055_a_2334_8525 crossref_primary_10_1002_oby_23711 crossref_primary_10_1007_s11357_022_00713_1 crossref_primary_10_1097_HC9_0000000000000014 crossref_primary_10_1126_sciadv_ads0535 crossref_primary_10_3168_jds_2022_21938 crossref_primary_10_1111_dom_15755 crossref_primary_10_3390_biomedicines10102540 crossref_primary_10_1017_S0007114524001673 crossref_primary_10_3390_metabo14010012 crossref_primary_10_3390_nu15112445 crossref_primary_10_15252_emmm_202318367 |
| Cites_doi | 10.1111/j.1749-6632.2002.tb04275.x 10.1093/nutrit/nuy022 10.1016/j.jhep.2021.04.013 10.1042/CS20030326 10.2337/dc18-0071 10.1186/s12944-017-0445-2 10.1038/s41467-020-15684-0 10.1210/jc.2019-00160 10.1155/2018/2784537 10.1371/journal.pmed.1003102 10.1016/S0140-6736(20)32511-3 10.1002/hep.25889 10.1038/oby.2009.326 10.1016/j.cmet.2019.06.002 10.3390/jcm10040792 10.1093/ajcn/nqz005 10.1016/j.numecd.2007.11.002 10.3945/ajcn.111.030114 10.3390/nu12113372 10.1053/j.gastro.2015.04.043 10.1002/hep.28431 10.1148/radiol.2019191035 10.3945/jn.112.171322 10.1016/j.diabres.2009.11.019 10.1097/EDE.0b013e318225c2be 10.1097/00075197-200203000-00002 10.1111/joim.12384 10.1016/j.mam.2018.03.001 10.1136/bmjdrc-2019-000871 10.2337/db13-1622 10.1038/s41419-018-1243-0 10.1038/srep46658 10.1016/j.jhep.2007.09.009 10.1111/liv.12685 10.1016/j.jhep.2017.07.027 10.2337/db08-1074 10.3945/ajcn.2008.26834 |
| ContentType | Journal Article |
| Copyright | Copyright © 2022 Fridén, Rosqvist, Ahlström, Niessen, Schultheis, Hockings, Hulthe, Gummesson, Wanders, Rorsman, Risérus and Vessby. Copyright © 2022 Fridén, Rosqvist, Ahlström, Niessen, Schultheis, Hockings, Hulthe, Gummesson, Wanders, Rorsman, Risérus and Vessby. 2022 Fridén, Rosqvist, Ahlström, Niessen, Schultheis, Hockings, Hulthe, Gummesson, Wanders, Rorsman, Risérus and Vessby |
| Copyright_xml | – notice: Copyright © 2022 Fridén, Rosqvist, Ahlström, Niessen, Schultheis, Hockings, Hulthe, Gummesson, Wanders, Rorsman, Risérus and Vessby. – notice: Copyright © 2022 Fridén, Rosqvist, Ahlström, Niessen, Schultheis, Hockings, Hulthe, Gummesson, Wanders, Rorsman, Risérus and Vessby. 2022 Fridén, Rosqvist, Ahlström, Niessen, Schultheis, Hockings, Hulthe, Gummesson, Wanders, Rorsman, Risérus and Vessby |
| DBID | AAYXX CITATION NPM 7X8 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC ABBSD F1S DOA |
| DOI | 10.3389/fmed.2021.814951 |
| DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) SWEPUB Uppsala universitet full text SwePub SwePub Articles SWEPUB Freely available online SWEPUB Uppsala universitet SwePub Articles full text SWEPUB Chalmers tekniska högskola full text SWEPUB Chalmers tekniska högskola DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic CrossRef PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2296-858X |
| ExternalDocumentID | oai_doaj_org_article_46315d45ba734f86ae00f9270542f8ce oai_research_chalmers_se_16995a01_96f3_462e_934c_1560e5c3bed9 oai_DiVA_org_uu_468792 PMC8784562 35083257 10_3389_fmed_2021_814951 |
| Genre | Journal Article |
| GrantInformation_xml | – fundername: ; – fundername: ; grantid: 20170492; 20200500 – fundername: ; grantid: 2016-01040; 2019-04756 |
| GroupedDBID | 53G 5VS 9T4 AAFWJ AAYXX ACGFS ACXDI ADBBV ADRAZ AFPKN ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV CITATION DIK GROUPED_DOAJ HYE KQ8 M48 M~E OK1 PGMZT RPM IAO IEA IHR IHW IPNFZ ISR NPM RIG 7X8 5PM ACNBI ADTPV AOWAS D8T DF2 ZZAVC ABBSD F1S |
| ID | FETCH-LOGICAL-c641t-c4ad297a5bb8176321847d877f7e825a49d901274e84447d3da3ccedc4fb64053 |
| IEDL.DBID | M48 |
| ISSN | 2296-858X |
| IngestDate | Wed Aug 27 01:32:05 EDT 2025 Thu Aug 21 06:33:24 EDT 2025 Thu Aug 21 06:51:00 EDT 2025 Thu Aug 21 18:20:16 EDT 2025 Fri Sep 05 13:42:04 EDT 2025 Thu Jan 02 22:56:03 EST 2025 Thu Apr 24 23:09:35 EDT 2025 Tue Jul 01 04:05:10 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Keywords | NAFLD lipids fibrosis fatty acids biomarkers |
| Language | English |
| License | Copyright © 2022 Fridén, Rosqvist, Ahlström, Niessen, Schultheis, Hockings, Hulthe, Gummesson, Wanders, Rorsman, Risérus and Vessby. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c641t-c4ad297a5bb8176321847d877f7e825a49d901274e84447d3da3ccedc4fb64053 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 This article was submitted to Gastroenterology, a section of the journal Frontiers in Medicine Reviewed by: Angelo Armandi, University of Turin, Italy; Metin Basaranoglu, Bezmiâlem Vakif Üniversitesi, Turkey Edited by: Ana Sandoval-Rodriguez, University of Guadalajara, Mexico These authors have contributed equally to this work and share last authorship |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3389/fmed.2021.814951 |
| PMID | 35083257 |
| PQID | 2623329165 |
| PQPubID | 23479 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_46315d45ba734f86ae00f9270542f8ce swepub_primary_oai_research_chalmers_se_16995a01_96f3_462e_934c_1560e5c3bed9 swepub_primary_oai_DiVA_org_uu_468792 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8784562 proquest_miscellaneous_2623329165 pubmed_primary_35083257 crossref_primary_10_3389_fmed_2021_814951 crossref_citationtrail_10_3389_fmed_2021_814951 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2022-01-10 |
| PublicationDateYYYYMMDD | 2022-01-10 |
| PublicationDate_xml | – month: 01 year: 2022 text: 2022-01-10 day: 10 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Frontiers in medicine |
| PublicationTitleAlternate | Front Med (Lausanne) |
| PublicationYear | 2022 |
| Publisher | Frontiers Media S.A |
| Publisher_xml | – name: Frontiers Media S.A |
| References | Roumans (B11) 2020; 11 Petersson (B36) 2010; 87 Fretts (B31) 2019; 109 Younossi (B1) 2016; 64 Araya (B15) 2004; 106 Lind (B22) 2020; 294 Kotronen (B23) 2010; 18 Rosqvist (B8) 2019; 104 Bedossa (B19) 2012; 56 Scorletti (B30) 2018; 64 Bergström (B17) 2015; 278 Saadatian-Elahi (B33) 2009; 89 Luukkonen (B10) 2018; 41 Enguita (B24) 2019; 10 Powell (B2) 2021; 397 Jang (B32) 2019; 30 Brenna (B27) 2002; 5 Rosqvist (B7) 2014; 63 Allard (B16) 2008; 48 Bjermo (B9) 2012; 95 Hagström (B3) 2017; 67 Ooi (B6) 2021; 75 Musa-Veloso (B29) 2018; 76 Depner (B26) 2013; 143 Vessby (B37) 2006; 967 Hajduch (B5) 2021; 10 Green (B25) 2020; 8 Kotronen (B13) 2009; 58 Angulo (B4) 2015; 149 Chiappini (B14) 2017; 7 Rosqvist (B18) 2017; 16 Textor (B20) 2011; 22 Warensjö (B34) 2008; 18 Yamada (B12) 2015; 35 Li (B21) 2018; 2018 Cansanção (B28) 2020; 12 Imamura (B35) 2020; 17 |
| References_xml | – volume: 967 start-page: 183 year: 2006 ident: B37 article-title: Desaturation and elongation of fatty acids and insulin action publication-title: Ann N Y Acad Sci doi: 10.1111/j.1749-6632.2002.tb04275.x – volume: 76 start-page: 581 year: 2018 ident: B29 article-title: Systematic review and meta-analysis of controlled intervention studies on the effectiveness of long-chain omega-3 fatty acids in patients with nonalcoholic fatty liver disease publication-title: Nutr Rev. doi: 10.1093/nutrit/nuy022 – volume: 75 start-page: 524 year: 2021 ident: B6 article-title: Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis publication-title: J Hepatol. doi: 10.1016/j.jhep.2021.04.013 – volume: 106 start-page: 635 year: 2004 ident: B15 article-title: Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease publication-title: Clin Sci. doi: 10.1042/CS20030326 – volume: 41 start-page: 1732 year: 2018 ident: B10 article-title: Saturated fat is more metabolically harmful for the human liver than unsaturated fat or simple sugars publication-title: Diabetes Care. doi: 10.2337/dc18-0071 – volume: 16 start-page: 68 year: 2017 ident: B18 article-title: Fatty acid composition in serum cholesterol esters and phospholipids is linked to visceral and subcutaneous adipose tissue content in elderly individuals: a cross-sectional study publication-title: Lipids Health Dis. doi: 10.1186/s12944-017-0445-2 – volume: 11 start-page: 1891 year: 2020 ident: B11 article-title: Hepatic saturated fatty acid fraction is associated with de novo lipogenesis and hepatic insulin resistance publication-title: Nat Commun. doi: 10.1038/s41467-020-15684-0 – volume: 104 start-page: 6207 year: 2019 ident: B8 article-title: Overeating saturated fat promotes fatty liver and ceramides compared with polyunsaturated fat: a randomized trial publication-title: J Clin Endocrinol Metab. doi: 10.1210/jc.2019-00160 – volume: 2018 start-page: 2784537 year: 2018 ident: B21 article-title: Nonalcoholic fatty liver disease cirrhosis: a review of its epidemiology, risk factors, clinical presentation, diagnosis, management, and prognosis publication-title: Can J Gastroenterol Hepatol. doi: 10.1155/2018/2784537 – volume: 17 start-page: e1003102 year: 2020 ident: B35 article-title: Fatty acids in the de novo lipogenesis pathway and incidence of type 2 diabetes: a pooled analysis of prospective cohort studies publication-title: PLoS Med. doi: 10.1371/journal.pmed.1003102 – volume: 397 start-page: 2212 year: 2021 ident: B2 article-title: Non-alcoholic fatty liver disease publication-title: Lancet. doi: 10.1016/S0140-6736(20)32511-3 – volume: 56 start-page: 1751 year: 2012 ident: B19 article-title: Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients publication-title: Hepatology. doi: 10.1002/hep.25889 – volume: 18 start-page: 937 year: 2010 ident: B23 article-title: Comparison of lipid and fatty acid composition of the liver, subcutaneous and intra-abdominal adipose tissue, and serum publication-title: Obesity. doi: 10.1038/oby.2009.326 – volume: 30 start-page: 594 year: 2019 ident: B32 article-title: Metabolite exchange between mammalian organs quantified in pigs publication-title: Cell Metab. doi: 10.1016/j.cmet.2019.06.002 – volume: 10 start-page: 792 year: 2021 ident: B5 article-title: Roles of ceramides in non-alcoholic fatty liver disease publication-title: J Clin Med. doi: 10.3390/jcm10040792 – volume: 109 start-page: 1216 year: 2019 ident: B31 article-title: Associations of circulating very-long-chain saturated fatty acids and incident type 2 diabetes: a pooled analysis of prospective cohort studies publication-title: Am J Clin Nutr. doi: 10.1093/ajcn/nqz005 – volume: 18 start-page: 683 year: 2008 ident: B34 article-title: Effects of saturated and unsaturated fatty acids on estimated desaturase activities during a controlled dietary intervention publication-title: Nutr Metab Cardiovasc Dis. doi: 10.1016/j.numecd.2007.11.002 – volume: 95 start-page: 1003 year: 2012 ident: B9 article-title: Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial publication-title: Am J Clin Nutr. doi: 10.3945/ajcn.111.030114 – volume: 12 start-page: 3372 year: 2020 ident: B28 article-title: Impact of long-term supplementation with fish oil in individuals with non-alcoholic fatty liver disease: a double blind randomized placebo controlled clinical trial publication-title: Nutrients. doi: 10.3390/nu12113372 – volume: 149 start-page: 389 year: 2015 ident: B4 article-title: Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease publication-title: Gastroenterology. doi: 10.1053/j.gastro.2015.04.043 – volume: 64 start-page: 73 year: 2016 ident: B1 article-title: Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes publication-title: Hepatology. doi: 10.1002/hep.28431 – volume: 294 start-page: 559 year: 2020 ident: B22 article-title: Voxel-wise study of cohort associations in whole-body MRI: application in metabolic syndrome and its components publication-title: Radiology. doi: 10.1148/radiol.2019191035 – volume: 143 start-page: 315 year: 2013 ident: B26 article-title: Docosahexaenoic acid attenuates hepatic inflammation, oxidative stress, and fibrosis without decreasing hepatosteatosis in a Ldlr(-/-) mouse model of western diet-induced nonalcoholic steatohepatitis publication-title: J Nutr. doi: 10.3945/jn.112.171322 – volume: 87 start-page: 379 year: 2010 ident: B36 article-title: Serum fatty acid composition and insulin resistance are independently associated with liver fat markers in elderly men publication-title: Diabetes Res Clin Pract. doi: 10.1016/j.diabres.2009.11.019 – volume: 22 start-page: 745 year: 2011 ident: B20 article-title: DAGitty publication-title: Epidemiology. doi: 10.1097/EDE.0b013e318225c2be – volume: 5 start-page: 127 year: 2002 ident: B27 article-title: Efficiency of conversion of alpha-linolenic acid to long chain n-3 fatty acids in man publication-title: Curr Opin Clin Nutr Metab Care. doi: 10.1097/00075197-200203000-00002 – volume: 278 start-page: 645 year: 2015 ident: B17 article-title: The Swedish CArdioPulmonary BioImage Study: objectives and design publication-title: J Intern Med. doi: 10.1111/joim.12384 – volume: 64 start-page: 135 year: 2018 ident: B30 article-title: Omega-3 fatty acids and non-alcoholic fatty liver disease: evidence of efficacy and mechanism of action publication-title: Mol Aspects Med. doi: 10.1016/j.mam.2018.03.001 – volume: 8 start-page: e000871 year: 2020 ident: B25 article-title: Hepatic de novo lipogenesis is suppressed and fat oxidation is increased by omega-3 fatty acids at the expense of glucose metabolism publication-title: BMJ Open Diabetes Res Care. doi: 10.1136/bmjdrc-2019-000871 – volume: 63 start-page: 2356 year: 2014 ident: B7 article-title: Overfeeding polyunsaturated and saturated fat causes distinct effects on liver and visceral fat accumulation in humans publication-title: Diabetes. doi: 10.2337/db13-1622 – volume: 10 start-page: 14 year: 2019 ident: B24 article-title: The cirrhotic liver is depleted of docosahexaenoic acid (DHA), a key modulator of NF-κB and TGFβ pathways in hepatic stellate cells publication-title: Cell Death Dis. doi: 10.1038/s41419-018-1243-0 – volume: 7 start-page: 46658 year: 2017 ident: B14 article-title: Metabolism dysregulation induces a specific lipid signature of nonalcoholic steatohepatitis in patients publication-title: Sci Rep. doi: 10.1038/srep46658 – volume: 48 start-page: 300 year: 2008 ident: B16 article-title: Nutritional assessment and hepatic fatty acid composition in non-alcoholic fatty liver disease (NAFLD): a cross-sectional study publication-title: J Hepatol. doi: 10.1016/j.jhep.2007.09.009 – volume: 35 start-page: 582 year: 2015 ident: B12 article-title: Characteristics of hepatic fatty acid compositions in patients with nonalcoholic steatohepatitis publication-title: Liver Int. doi: 10.1111/liv.12685 – volume: 67 start-page: 1265 year: 2017 ident: B3 article-title: Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD publication-title: J Hepatol. doi: 10.1016/j.jhep.2017.07.027 – volume: 58 start-page: 203 year: 2009 ident: B13 article-title: Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver publication-title: Diabetes. doi: 10.2337/db08-1074 – volume: 89 start-page: 331 year: 2009 ident: B33 article-title: Plasma phospholipid fatty acid profiles and their association with food intakes: results from a cross-sectional study within the European Prospective Investigation into Cancer and Nutrition publication-title: Am J Clin Nutr. doi: 10.3945/ajcn.2008.26834 |
| SSID | ssj0001325413 |
| Score | 2.2898934 |
| Snippet | Background:
The hepatic lipidome of patients with early stages of non-alcoholic fatty liver disease (NAFLD) has been fairly well-explored. However, studies on... The hepatic lipidome of patients with early stages of non-alcoholic fatty liver disease (NAFLD) has been fairly well-explored. However, studies on more... Background: The hepatic lipidome of patients with early stages of non-alcoholic fatty liver disease (NAFLD) has been fairly well-explored. However, studies on... |
| SourceID | doaj swepub pubmedcentral proquest pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 814951 |
| SubjectTerms | biomarkers fatty acids fibrosis lipids Medicine NAFLD |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lj9MwELbQHhAXxJvwkpHgwCFsYjt-HAulqlB3TxTtzXIcW61ACSLpYf_9zsTZaiNWcOGa2Knrb2LPlxl_Q8g7WdZYxJrnEaw3FyH6vGYMFkMhohGMhaLGw8ln53K9FV8vqosbpb4wJyzJA6eJOxWSl1UjqtopLqKWLhRFNEyBq8Gi9gFXX9jGbpCp8esKB-JT8hSXBBZmAKaAwqCs_KiRFJSzfWiU67_Nx_wzVXImKDpuQqsH5P7kPdJFGvVDcie0j8jdsyk-_pj8WAfMkPZ02_ao2AmOZENXbhgu6cLvmx56Bor0Ey4PHd1giTS6DMC5A-0iXQF37vp9T_ctPe_a3KX6ufC89IwNJnHQZYrpPCHb1Zdvn9f5VE4h91KUQ-6Fa5hRrqprXcKyguRONVqpqALwRCdMYzAQLQIABXd447j38NdFrCX4dfwpOWm7NjwnVDfRucp5bTDK6l3NIndGSBG9M66QGTm9nlzrJ61xLHnx0wLnQDgswmERDpvgyMiHY49fSWfjL20_IV7HdqiQPV4Au7GT3dh_2U1G3l6jbeGNwjCJa0N36C0Dj5AzcJurjDxL6B9_iqN6PqxyGVEzu5iNZX6n3e9G1W6tNLLNjLxPFjTrstx_X4zDPxxg5FoZaLe5pd2kALWzfjeW1-ltH2wpjalcUVojI4fuLFjDhbd4SD5UntehMS_-x5y9JPcYnv4oMAvyFTkZfh_Ca_DJhvrN-PpdAUxSNBY priority: 102 providerName: Directory of Open Access Journals |
| Title | Hepatic Unsaturated Fatty Acids Are Linked to Lower Degree of Fibrosis in Non-alcoholic Fatty Liver Disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/35083257 https://www.proquest.com/docview/2623329165 https://pubmed.ncbi.nlm.nih.gov/PMC8784562 https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-468792 https://research.chalmers.se/publication/528478 https://doaj.org/article/46315d45ba734f86ae00f9270542f8ce |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: KQ8 dateStart: 20140101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: DOA dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVBFR databaseName: Free Medical Journals customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: DIK dateStart: 20140101 isFulltext: true titleUrlDefault: http://www.freemedicaljournals.com providerName: Flying Publisher – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: M~E dateStart: 20140101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVAQN databaseName: PubMed Central customDbUrl: eissn: 2296-858X dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: RPM dateStart: 20140101 isFulltext: true titleUrlDefault: https://www.ncbi.nlm.nih.gov/pmc/ providerName: National Library of Medicine – providerCode: PRVFZP databaseName: Scholars Portal Journals: Open Access customDbUrl: eissn: 2296-858X dateEnd: 20250131 omitProxy: true ssIdentifier: ssj0001325413 issn: 2296-858X databaseCode: M48 dateStart: 20141201 isFulltext: true titleUrlDefault: http://journals.scholarsportal.info providerName: Scholars Portal |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nj9MwELXQIiEuaPkOHysjwYFDlsR2HPuAUKFUFWr3RFFvluPYtGKVsE0qsf-emSRbFFEhrontOJmx_V7GfkPIa5kWmMSaxwG8NxY-uLhgDCZDIYIWjPmkwMPJyws5X4kv62z953j08AGbo9QO80mtdpfnv66uP8CAf4-ME9ZbsIBHzU-WnivE-8CFbsO6xNDHlwPY7_64cCBDXb5kxrSMVabWfdzyaCOjdaqT8z-GQf_eSjkSHO0WqdkpuTegSzrp3eE-ueWrB-TOcoifPyQ_5h53UDu6qhpU9ASgWdKZbdtrOnHbsoGaniI9hcttTReYQo1OPXByT-tAZ8Ct62bb0G1FL-oqtn1-XWivb2OBmzzotI_5PCKr2eevn-bxkG4hdlKkbeyELZnObVYUKoVpB8lfXqo8D7kHHmmFLjUGqoUHQ8IdXlruHLy6CIUE3Mcfk5OqrvxTQlUZrM2sUxqjsM4WLHCrhRTBWW0TGZF3Nx_XuEGLHFNiXBrgJGgOg-YwaA7TmyMibw81fvY6HP8o-xHtdSiHCtrdhXr33QwD0gjJ06wUWWFzLoKS1idJ0CwHCMuCcj4ir26sbWDEYRjFVr7eN4YBYuQMYHUWkSe99Q-P4qiuD7NgRPKRX4z6Mr5TbTedqrfKFbLRiLzpPWhUZbr9Num6v99Dz1WuodziSLlBIWpj3KZLv9OYxptUap3ZJDVaBg7VmTeaC2fwEL3PHC98qZ_952Ofk7sMD4AkuBHyBTlpd3v_EmBZW5x1vzPOujH3G1zgNrY |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Hepatic+Unsaturated+Fatty+Acids+Are+Linked+to+Lower+Degree+of+Fibrosis+in+Non-alcoholic+Fatty+Liver+Disease&rft.jtitle=Frontiers+in+medicine&rft.au=Frid%C3%A9n%2C+Michael&rft.au=Rosqvist%2C+Fredrik&rft.au=Ahlstr%C3%B6m%2C+H%C3%A5kan&rft.au=Niessen%2C+Heiko+G.&rft.date=2022-01-10&rft.issn=2296-858X&rft.eissn=2296-858X&rft.volume=8&rft_id=info:doi/10.3389%2Ffmed.2021.814951&rft.externalDocID=oai_DiVA_org_uu_468792 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2296-858X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2296-858X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2296-858X&client=summon |